Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) are first-line treatments for non-small cell lung cancer (NSCLC).
• Therapeutic resistance to TKIs significantly limits their clinical efficacy in NSCLC treatment.
• The role of specific molecular markers in mediating TKI resistance remains an area of active investigation.

Purpose of the Study:

• To investigate the role of Octamer-binding transcription factor 4 (OCT4) in the development of resistance to EGFR-targeted TKIs in NSCLC.
• To determine the correlation between OCT4 expression levels and TKI sensitivity in NSCLC cells.
• To explore the potential of targeting OCT4 to overcome gefitinib resistance.

Main Methods:

• Quantitative analysis of OCT4 expression in NSCLC tissues versus adjacent non-tumourous tissues.
• In vitro knockdown of OCT4 expression in NSCLC cell lines.
• Assessment of cell proliferation and apoptosis following OCT4 knockdown and gefitinib treatment.

Main Results:

• A statistically significant difference in OCT4 expression was observed between NSCLC and non-tumourous tissues.
• Knockdown of OCT4 in NSCLC cells led to decreased cell proliferation.
• Reduced OCT4 expression potentiated gefitinib-induced apoptosis in NSCLC cells.

Conclusions:

• OCT4 expression is significantly different in NSCLC compared to normal tissues.
• OCT4 plays a crucial role in promoting cell proliferation and conferring resistance to gefitinib in NSCLC.
• Targeting OCT4 may represent a viable strategy to enhance the efficacy of gefitinib therapy for NSCLC patients.